Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites Clinical Trial

Official title:

A Phase Ia/Ib, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting VEGFR1 and PD-L1 CAR-T in Cancer Patients With Pleural or Peritoneal Metastases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05477927
• Other study ID #: MCART-006
• Status: Recruiting
• Phase: Phase 1
• Start date: November 28, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2023
• Source: Sichuan University
• Contact: XIA HE, Ph.D
• Phone: 18583365730
• Email: 18583365730[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Serosal cavity metastases of malignant tumor seriously affects the quality of life and survival time of patients with cancers in advanced stage. VEGFR1 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors and their metastases. The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in cancer patients with serosal cavity metastases.

Description:

In this study, VEGFR1 will be used as the general target of serosal cavity metastasis of malignant tumor, and the dual-targeting CAR-T of VEGFR1/PD-L1 will be injected in to pleural or peritoneal cavity of patients with advanced serous cavity metastases, such as ovarian cancer, breast cancer, lung cancer and gastric cancer, who had nearly no response to standard treatment. The safety and effectiveness will be evaluated. The safety evaluation standard refers to the standard of CTCAE 5.0. The evaluation standard of effectiveness refers to the evaluation standard of solid tumor curative effect RECIST 1.1 to evaluate the curative effect.

There are two part of this study, the first is dose escalation part, 18 patients with malignant tumor (failure of standard treatment will be enrolled at least, patients with peritonea cavity metastases are planned to be enrolled in the cohort 1, and those with pleural cavity metastasis are enrolled in the cohort 2. The second is dose expansion part, the curative effect has observed in the first part, and after the DLT observation period of the related dose group was finished, the PI will decided whether to conduct the dose expansion research finally. It was planned to enroll 40 patients with serous cavity metastases , two cohorts were divided the same as mentioned above in dose escalation part.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female, Age 18-65 years old; negative results of serum or urine pregnancy test within 48 hours before treatment are needed to provide for fertile women (or women who have undergone sterilization or at least 2 years after menopause can be regarded as infertile);

2. Patients diagnosed as ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, etc., accompanied by serous cavity metastasis, have received systemic standard treatment, and have clinical symptoms of serous cavity metastasis;

3. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;

4. Estimated life expectancy = 3 months (according to investigator's judgement);

5. Absolute neutrophil count = 1.5×10^9/L, platelet count = 90×10^9/L, absolute lymphocyte count =1×10^8/L, hemoglobin = 9.0 g/dL;

6. Creatinine clearance rate =60 mL/min, Serum ALT/AST=2.5 times of the normal level, and total bilirubin=1.5 times of the normal level;

7. Cardiac ejection fraction =50%, no pericardial effusion;

8. No other serious diseases (autoimmune diseases or any immune deficiency disease or other disease in need of immunosuppressive therapy);

9. Patients must stop chemotherapy and targeted therapy for at least 3 weeks before starting treatment;

10. Patients must take reliable contraceptive measures before entering the trial, during the research process until 1 year after CAR-T infusion; reliable contraceptive measures will be determined by the main investigator or designated personnel;

11. Voluntarily participate in the research, understand and sign the informed consent;

12. The side effect of the last anti-tumor treatment was reduced to =1 grade, except for hair loss.

Exclusion Criteria:

1. Had accepted any treatment of CAR-T therapy;

2. Allergic to cytokines; uncontrolled activity infection;

3. Acute or chronic (graft-versus-host disease) GVHD;

4. Accompanied by other uncontrolled malignant tumors;

5. Patient with hepatitis B or C active period, HIV infection = the upper limit of the normal level;

6. Other uncontrolled diseases in active period that hinder participation in the trial;

7. Suffer from serious diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.;

8. Patients with grade 2-3 hypertension or poorly controlled;

9. History of mental illness that is difficult to control;

10. Patients have used immunosuppressive agents for a long time after organ transplantation, except for recent or current inhaled corticosteroid therapy;

11. The existing medical history or mental state history or laboratory abnormalities may increase the risk associated with participating in the study or the administration of the study drug from the point view of PI;

12. Unstable pulmonary embolism, deep venous embolism or other major arterial/venous thromboembolic events occurred within 6 months before enrollment. If receiving anticoagulant therapy;

13. Pregnant or nursing women, or plan to become pregnant during the treatment period or within 1 year after the treatment ends;

14. Female subjects of childbearing age were reluctant to accept high-efficiency contraceptive measures during the treatment period or within 1 year after the treatment ends;

15. Patient suffering from diseases that have signed written informed consent or comply with research procedures; or are unwilling or unable to comply with research requirements;

16. Patients who are inappropriate to participate in this experiment as considered by PI.

Related Conditions & MeSH terms

• Ascites
• Malignant Ascites
• Neoplasm Metastasis

Intervention

Biological:
• Dual-targeting VEGFR1 and PD-L1 CAR-T cells
In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design. In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition.

Locations

Country	Name	City	State
China	West China Hospital, Sichuan University	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan University

Country where clinical trial is conducted

China, 

References & Publications (2)

Cheema PK, Burkes RL. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. Curr Oncol. 2013 Apr;20(2):e150-60. doi: 10.3747/co.20.1226. — View Citation

Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):379-393. doi: 10.1038/s41571-021-00476-2. Epub 2021 Feb 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AEs will be recorded and evaluated by CTCAT 5.0.	Safety	28 days
Primary	Recommended phase II dose (RP2D).	Efficacy dose	Approximately 18 months.
Primary	Therapeutic efficacy will be evaluated according to RECIST1.1.	Ant-tumor effects	Approximately 18 months.
Primary	Dose-limiting toxicity (DLT) will be assessed by CTCAE 5.0.	Tolerability evaluation	28 days
Secondary	Objective Remission Rate (ORR).	Include CR (complete response) and PR (partial response).	3 months
Secondary	Progression-Free Survival (PFS ).	The time from CAR-T administration to disease progression or death.	Approximately 18 months.
Secondary	Duration Of Control Rate (DCR).	The number of cases in which response (PR + CR) and stable disease (SD) are achieved from the start of cell infusion/the total number of evaluable cases (%).	3 months
Secondary	Duration Of Response (DOR).	It refers to the time from the first evaluation of CR or PR to the first evaluation of PD(Progressive Disease) or death from any reason.	Approximately 18 months.
Secondary	Overall-Survival (OS).	It defined as the time from randomization to death from any cause, is a direct measure of clinical benefit to a patient. Patients alive or lost to follow-up are censored.	Approximately 18 months.
Secondary	Anti-CAR antibody production	Immunogenicity	12 months.
Secondary	CAR-T cell numbers.	PK/PD	12 months.